Effects of atypical antipsychotics and haloperidol on PC12 cells: only aripiprazole phosphorylates AMP-activated protein kinase

[1]  Jun Xu,et al.  Oligomycin-induced Bioenergetic Adaptation in Cancer Cells with Heterogeneous Bioenergetic Organization , 2010, The Journal of Biological Chemistry.

[2]  B. Viollet,et al.  PKA phosphorylates and inactivates AMPKα to promote efficient lipolysis , 2010, The EMBO journal.

[3]  T. Horvath,et al.  UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals , 2009, Nature.

[4]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[5]  G. Ronnett,et al.  AMPK in the brain: its roles in energy balance and neuroprotection , 2009, Journal of neurochemistry.

[6]  S. Chua,et al.  Oleic acid directly regulates POMC neuron excitability in the hypothalamus. , 2009, Journal of neurophysiology.

[7]  Satoshi O. Suzuki,et al.  Inhibitory effects of aripiprazole on interferon‐γ‐induced microglial activation via intracellular Ca2+ regulation in vitro , 2008, Journal of neurochemistry.

[8]  Ricardo Lage,et al.  Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. , 2008, Cell metabolism.

[9]  J. Lieberman,et al.  Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway , 2008, Molecular Psychiatry.

[10]  H. Vedder,et al.  Effects of haloperidol, clozapine and olanzapine on the survival of human neuronal and immune cells in vitro , 2007, Journal of psychopharmacology.

[11]  B. Lowell,et al.  Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity , 2007, Nature.

[12]  Yanying Fan,et al.  Neuroprotective effect of carnosine on necrotic cell death in PC12 cells , 2007, Neuroscience Letters.

[13]  G. Rutter,et al.  Glucose sensing by hypothalamic neurones and pancreatic islet cells: AMPle evidence for common mechanisms? , 2007, Experimental physiology.

[14]  S. Snyder,et al.  Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase , 2007, Proceedings of the National Academy of Sciences.

[15]  L. Renaud,et al.  Pharmacological and molecular characterization of ATP-sensitive K+ conductances in CART and NPY/AgRP expressing neurons of the hypothalamic arcuate nucleus , 2007, Neuroscience.

[16]  K. Mori,et al.  Risperidone reduces mRNA expression levels of Sulfonylurea Receptor 1 and TASK1 in PC12 cells , 2007, Neuroscience Letters.

[17]  Ruoyan Chen,et al.  Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies , 2007, Psychopharmacology.

[18]  D. Carling,et al.  Thrombin Activates AMP-Activated Protein Kinase in Endothelial Cells via a Pathway Involving Ca2+/Calmodulin-Dependent Protein Kinase Kinase β , 2006, Molecular and Cellular Biology.

[19]  D. Hardie,et al.  Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca2+ in T lymphocytes , 2006, The Journal of experimental medicine.

[20]  Geoffrey C. Williams,et al.  Prevalence of the metabolic syndrome among patients receiving clozapine. , 2006, The American journal of psychiatry.

[21]  Colin G. Nichols,et al.  KATP channels as molecular sensors of cellular metabolism , 2006, Nature.

[22]  L. Rossetti,et al.  Molecular disruption of hypothalamic nutrient sensing induces obesity , 2006, Nature Neuroscience.

[23]  A. Edelman,et al.  Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. , 2005, Cell metabolism.

[24]  R. Kerwin,et al.  Partial agonism and schizophrenia , 2005, British Journal of Psychiatry.

[25]  Paul Ernsberger,et al.  H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[26]  D. Hardie,et al.  Management of cellular energy by the AMP‐activated protein kinase system , 2003, FEBS letters.

[27]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[28]  Roberto Conti,et al.  Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production , 2003, Nature Medicine.

[29]  E. Park,et al.  Upstream Stimulatory Factor Represses the Induction of Carnitine Palmitoyltransferase-Iβ Expression by PGC-1* , 2003, The Journal of Biological Chemistry.

[30]  D. S. Cowen,et al.  Activation of Extracellular-Regulated Kinase by 5-Hydroxytryptamine2A Receptors in PC12 Cells is Protein Kinase C-Independent and Requires Calmodulin and Tyrosine Kinases , 2002, Journal of Pharmacology and Experimental Therapeutics.

[31]  S. Marder,et al.  The effects of novel antipsychotics on glucose and lipid levels. , 2002, The Journal of clinical psychiatry.

[32]  W. Ho,et al.  A convenient one-step extraction of cellular ATP using boiling water for the luciferin-luciferase assay of ATP. , 2002, Analytical biochemistry.

[33]  Kevin D Burris,et al.  Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors , 2002, Journal of Pharmacology and Experimental Therapeutics.

[34]  C. Altar,et al.  The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. , 2002, European journal of pharmacology.

[35]  M. Moore,et al.  A region in the first exon/intron of rat carnitine palmitoyltransferase Iβ is involved in enhancement of basal transcription , 2002 .

[36]  J. Stuart,et al.  Superoxide activates mitochondrial uncoupling proteins , 2002, Nature.

[37]  B. Lowell,et al.  A significant portion of mitochondrial proton leak in intact thymocytes depends on expression of UCP2 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Young-Bum Kim,et al.  Uncoupling Protein-2 Negatively Regulates Insulin Secretion and Is a Major Link between Obesity, β Cell Dysfunction, and Type 2 Diabetes , 2001, Cell.

[39]  C. Townsend,et al.  Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. , 2000, Science.

[40]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[41]  David R. Sibley,et al.  Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes , 1999, Neuropsychopharmacology.

[42]  D. Kelly,et al.  Fatty Acids Activate Transcription of the Muscle Carnitine Palmitoyltransferase I Gene in Cardiac Myocytes via the Peroxisome Proliferator-activated Receptor α* , 1998, The Journal of Biological Chemistry.

[43]  E. Pothos,et al.  D2-Like Dopamine Autoreceptor Activation Reduces Quantal Size in PC12 Cells , 1998, The Journal of Neuroscience.

[44]  F. Hegardt,et al.  Control of Human Muscle-type Carnitine Palmitoyltransferase I Gene Transcription by Peroxisome Proliferator-activated Receptor* , 1998, The Journal of Biological Chemistry.

[45]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.

[46]  J. McGarry,et al.  In support of the roles of malonyl-CoA and carnitine acyltransferase I in the regulation of hepatic fatty acid oxidation and ketogenesis. , 1979, The Journal of biological chemistry.

[47]  J. McGarry,et al.  Carnitine palmitoyltransferase I. The site of inhibition of hepatic fatty acid oxidation by malonyl-CoA. , 1978, The Journal of biological chemistry.

[48]  T. Ono,et al.  Glucose and Osmosensitive Neurones of the Rat Hypothalamus , 1969, Nature.

[49]  B. Anand,et al.  ACTIVITY OF SINGLE NEURONS IN THE HYPOTHALAMIC FEEDING CENTERS: EFFECT OF GLUCOSE. , 1964, The American journal of physiology.

[50]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[51]  J. Mayer.  REGULATION OF ENERGY INTAKE AND THE BODY WEIGHT: THE GLUCOSTATIC THEORY AND THE LIPOSTATIC HYPOTHESIS , 1955, Annals of the New York Academy of Sciences.

[52]  J. Mayer.  Genetic, traumatic and environmental factors in the etiology of obesity. , 1953, Physiological reviews.

[53]  J. Mayer.  GLUCOSTATIC MECHANISM OF REGULATION OF FOOD INTAKE , 1953, The New England journal of medicine.

[54]  H. Nasrallah,et al.  Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles , 2008, Molecular Psychiatry.

[55]  R. Mailman,et al.  Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways , 2007, Neuropsychopharmacology.

[56]  Y. Sawada,et al.  Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. , 2005, Drug metabolism and pharmacokinetics.

[57]  Demetrios Vavvas,et al.  Malonyl-CoA, fuel sensing, and insulin resistance. , 1999, American journal of physiology. Endocrinology and metabolism.

[58]  M. Carlson,et al.  The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? , 1998, Annual review of biochemistry.

[59]  D. Hardie,et al.  The AMP-activated protein kinase--fuel gauge of the mammalian cell? , 1997, European journal of biochemistry.

[60]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.